botulinum toxin type A
Approved · FDA / EMAAlso known as BTX - A, BTX A, BTX-A, Botox+12 more
BTX - A, BTX A, BTX-A, Botox, Botox Cosmetic, Botulinum A neurotoxin, Botulinum toxin A, Daxxify, Dysport, Jeuveau, Letybo, Toxina botulínica A, Toxine botulinique A, Xeomin, Botulinum antitoxin type A, Botulinum toxin type-A.
Recent clinical, regulatory, research and industry developments relating to this drug.
Indication expansion: INCOBOTULINUMTOXINA (BLA125360)
Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis
Label change: INCOBOTULINUMTOXINA (BLA125360)
Label change: INCOBOTULINUMTOXINA (BLA125360)
Label change: INCOBOTULINUMTOXINA (BLA125360)
Is botulinum toxin A effective for the treatment of plantar fasciitis?
A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial… Show full indicationShow less
Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Botulinum Toxin in Open Abdomen Closure
Botulinum Toxin-A for Hidradenitis Suppurativa
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- BMJ open2
- JAMA dermatology1
- Journal of neurology, neurosurgery, and psychiatry1
- Parkinsonism & related disorders1
- The American journal of gastroenterology1
- The Clinical journal of pain1
- Hefter H2
- Jost W2
- Bamford JM1
- Benecke R1
- Bhakta BB1
- Brashear A1
- Brodsky M1
- Chamberlain MA1
- University of Düsseldorf2
- Center for Cancer Research1
- Laboratory of Pathology1
- Office of the Clinical Director1
- Temple University School of Medicine1
- The Parkinson's and Movement Disorder Institute1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.